Walleye Capital LLC Takes $420,000 Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Walleye Capital LLC purchased a new stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRXGet Rating) during the 1st quarter, HoldingsChannel.com reports. The institutional investor purchased 200,968 shares of the biopharmaceutical company’s stock, valued at approximately $420,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Teacher Retirement System of Texas bought a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $43,000. Bank of Montreal Can bought a new position in shares of Lexicon Pharmaceuticals in the 1st quarter valued at $26,000. GSA Capital Partners LLP acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter valued at $124,000. SG Americas Securities LLC boosted its holdings in shares of Lexicon Pharmaceuticals by 69.9% during the 1st quarter. SG Americas Securities LLC now owns 33,720 shares of the biopharmaceutical company’s stock valued at $70,000 after acquiring an additional 13,876 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter valued at $186,000.

Insider Transactions at Lexicon Pharmaceuticals

In other Lexicon Pharmaceuticals news, Director International S.C.A. Artal acquired 16,173,800 shares of the stock in a transaction dated Monday, August 1st. The stock was purchased at an average cost of $2.50 per share, with a total value of $40,434,500.00. Following the transaction, the director now owns 48,433,261 shares in the company, valued at approximately $121,083,152.50. The acquisition was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 6.50% of the company’s stock.

Lexicon Pharmaceuticals Stock Down 3.3 %

Shares of LXRX opened at $2.37 on Friday. The company has a market capitalization of $435.19 million, a PE ratio of -3.65 and a beta of 1.43. Lexicon Pharmaceuticals, Inc. has a 12 month low of $1.31 and a 12 month high of $6.33. The stock’s 50-day moving average price is $2.82 and its two-hundred day moving average price is $2.30. The company has a current ratio of 3.85, a quick ratio of 3.85 and a debt-to-equity ratio of 0.33.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Citigroup raised their price objective on Lexicon Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a report on Friday, July 1st. Piper Sandler assumed coverage on Lexicon Pharmaceuticals in a report on Friday, August 12th. They set an “overweight” rating and a $10.00 price objective on the stock.

Lexicon Pharmaceuticals Company Profile

(Get Rating)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.

See Also

Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRXGet Rating).

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.